Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clavulanic Acid for Cocaine Use Disorder
NCT05562349Phase 2Active, not recruiting
- Sponsor
- Temple University
- Start
- May 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of clavulanic acid in cocaine use disorder (CUD), sponsored by Temple University. Primary endpoint: Relapse to cocaine use at 12 weeks. Started May 2023; status: active, not recruiting.
02
Drugs
clavulanic acid
03
Conditions
cocaine use disorder (CUD)
Beyond the preview
Go deeper on NCT05562349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05562349.